This increase in scientific personnel, with an administrative team still limited to two people, reflects our focus on research and development first».
On the scientific side, Mr Patrick Daoust, one of the two Research Directors overseeing the development of the product added: «With a team of trained scientists working on cell lines development and product characterization, real progress is being made towards the milestones set for Viropro's first international contract. This will better allow the company to move forward with the development of the subsequent monoclonal antibodies in the pipeline in partnership with major pharmaceutical groups worldwide».
About Viropro Inc.
Viropro Inc., a public company incorporated under the laws of the state of Nevada, operates through a Canadian subsidiary called Viropro International Inc. The company does business in the pharmaceutical sector and specializes in the development of manufacturing processes for the production of generic biopharmaceutical drugs. The manufacturing processes developed are out-licensed to various international partners who produce and distribute the final product. Viropro's revenues come from license fees from technology transfers and royalties from the sale of final product.
Viropro Inc. Safe Harbor Statement
Except for any historic information contained herein, the matters discussed in this press release contain forward-looking statements that involve risks and uncertainties, which are subject to section 27A of the Securities Act of 1933 and section 21E of the Exchange Act of 1934, and are subject to safe harbor created by these sections. Any statements that express or involve discussions with respect to predictions, beliefs, plans, projections, objectives, goals, assumptions of future events or performances are not statements of historical fact and may be "forward-looking statements". Forward-looking statements in this release may be identified through the use of such words as "expects", "anticipates", "estimates", "believes", or statements indicating certain actions "may", "could", or "might" occur. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements, which involve numerous risks and uncertainties, including the Company's ability to market its products and services in a competitive environment as well as other factors.
For more information on Viropro Inc., please visit our website on www.viropro.com
Viropro:
info@viropro.com
(514) 731-8776 ext. 223
Copyright (c) 2008 Thenewswire.ca - All rights reserved.
